Cardiorespiratory coupling is associated with exercise capacity in patients with chronic obstructive pulmonary disease

Yu-Chen Huang, MD, Ting-Yu Lin, MD, Hau-Tieng Wu, MD, PhD, Po-Jui Chang, MD, PhD, Chun-Yu Lo, MD, PhD, Tsai-Yu Wang, MD, Chih-Hsi Scott Kuo, MD, Shu-Min Lin, MD, Fu-Tsai Chung, MD, Horng-Chyuan Lin, MD, Meng-Heng Hsieh, MD, Yu-Lun Lo, MD

1 Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
2 College of Medicine, Chang Gung University, Taoyuan, Taiwan
3 Department of Mathematics, Duke University, Durham, NC, USA
4 Department of Statistical Sciences, Duke University, Durham, NC, USA

Running title: Cardiorespiratory coupling in COPD

Corresponding to:
Yu-Lun Lo MD
Department of Thoracic Medicine
Chang Gung Memorial Hospital
199 Tun-Hwa N. Rd.,
Taipei, Taiwan
Fax: 886 33272474.
E-mail: loyulun@hotmail.com

This study was supported by a grant from the Taiwan Ministry of Science and Technology, 107-2314-B-182A-145-MY2.
Abstract

Background: Although comorbidities of cardiovascular disease is common in patients with chronic obstructive pulmonary disease (COPD), the interaction between the heart and lungs in COPD patients has yet to be further elucidated. Synchrogram index is a new parameter that can quantify this interaction and has the potential to apply in COPD patients.

Aim: Our objective in this study was to characterize cardiorespiratory interactions in terms of cardiorespiratory coupling (CRC) using the synchrogram index of the heart rate and respiratory flow signals in patients with chronic obstructive pulmonary disease.

Methods: This is a cross-sectional and a preliminary data from a prospective study, examining 55 COPD patients. K-means clustering analysis was applied to cluster COPD patients based on synchrogram index. Linear regression and multivariable regression analysis were used to determine the correlation between the synchrogram index and the exercise capacity assessed by six-minute walking test (6MWT).

Results: The 55 COPD patients were separated into a synchronized group (median 0.89 (0.64-0.97), n=43) and a desynchronized group (median 0.23 (0.02-0.51), n=12) based on K-means clustering analysis. Synchrogram index was correlated significantly with six minutes walking distance (r=0.42, p=0.001) and distance
saturation product ($r=0.41$, $p=0.001$) assessed by 6MWT, and still was an independent variable by multivariable regression analysis.

**Conclusion:** This is the first result studying the heart-lung interaction in terms of cardiorespiratory coupling in COPD patients by the synchrogram index, and COPD patients are clustered into synchronized and desynchronized groups. Cardiorespiratory coupling is associated with exercise capacity in patients with COPD.

**Key Words:** Heart-lung interaction, synchrogram index, six-minute walking distance, distance saturation product.
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitations resulting from the inflammation and narrowing of peripheral airway, destruction of the alveolar attachment, and loss of small airways [1-3]. Possible causes include exposure to or inhalation of noxious gases or particles and systemic inflammation. COPD has been shown to affect nutritional status, exercise tolerance, and the cardiovascular system [4]. The prevalence of cardiovascular disease as a comorbidity and cause of mortality underlines the need to consider the interaction between the heart and lungs in patients with COPD [5-7].

Heart-lung interactions can be classified according to the underlying related but different mechanisms: (i) respiratory sinus arrhythmia, (ii) cardioventilatory coupling, and (iii) respiratory stroke volume synchronization [8]. For example, during inspiration, central inspiratory drive [9] and negative intrathoracic pressure [10] both contribute to an increase in heart rate [11]. Negative intrathoracic pressure promotes filling of the right ventricle and impedes filling of the left ventricle [12]. A decrease in arterial blood pressure tends to increase respiratory rate and tidal volume through the baroreflex [13]. Since heart-lung interactions was affected by several mechanisms as mentioned before, a proper quantification of cardiorespiratory coupling (CRC) is
an intuitive method to depict it. It has been used to study the heart-lung interactions in control subjects [14], infants [15], and in identifying sleep stages [16].

To our knowledge, CRC has not been systematically evaluated in patients. Under the clinical observation of intimate relationship between heart and lung in patients with COPD [17], a proper quantification of CRC would be beneficial for clinical application. The aim of this study was to apply synchrogram index to evaluate the CRC in patients with COPD, and to cluster patients based on their synchrogram index.

Methods

Study Design and Patients

This observational cross-sectional study was a preliminary data from a conducting prospective study at Chang Gung Memorial Hospital since January in 2019. Included patients were those with a clinical diagnosis COPD, based on the Global Initiative for Obstructive Lung Disease Criteria (GOLD), with the exclusive criteria: patients with congestive heart failure (ejection fraction <40%), known malignancy, or atrial fibrillation as well as those using anti-arrhythmic agents for arrhythmia or oxygen. All COPD patients underwent cardiac echo analysis, biochemical analysis (eosinophils, high sensitivity C-reactive protein (HS-CRP), and IgE), pulmonary function tests, chest high-resolution CT (HRCT) scanning, a six-minute walking test
(6MWT) and a coupling test during the first visit of enrollment. Emphysema was defined based on chest HRCT report from the radiologist and one pulmonologist [18].

Clinical profiles, a list of inhalation medicines, anti-psychotic agents, result of emphysema based on HRCT and acute exacerbation history [19] were also recorded. Although there is one patient who presented high ratio of FEV₁/FVC before exercise (0.72) and after exercise (0.73), he was not excluded as the spirometry fulfilled the GOLD guideline when he was diagnosed COPD. The remaining 55 patients with COPD (69 (51-84) years old, 54 male) (Figure 1). All participants signed informed consent prior to enrollment. The study was approved by the Ethics Committee of Chang Gung Memorial Hospital, Linkou, Taiwan (201702150B0).

**Six-minute walking test**

The 6MWT was carried out on the smooth surface and straight aisle with interval of 30 meters. Before the exam, patients were rest in a sitting position and performed spirometry before exercise to assess the pulmonary function, including the flow volume and tidal volume based on the guideline [20]. Meanwhile, oxygen saturation, heart rate, arterial blood pressure, and Borg scale in assessing the degree of dyspnea were recorded. Then, they were instructed to walk as soon as possible in six minutes. They could stop and take the rest when they felt tired or dyspnea, then restarted if they are available as soon as possible. The instructors were avoided to
walk with the subjects but stood at the fixed area giving encouraging sentences with
even tone every minute and 15 second before the end of the exam according to the
American Thoracic Society (ATS) guideline [21, 22]. Oxygen saturation and heart
rate can be recorded in real time during the course of walking. At the end of the exam,
walking distance, oxygen saturation, distance saturation product (i.e., the product of
nadir saturation during exercise and walking), heart rate and Borg scale were recorded
and patients performed spirometry again after exercise.

**Phase synchronization analysis**

**Instrumentation**

Experiments were performed in a quiet room with the temperature maintained at
22-24 °C. Participants were instructed to avoid inhalation short acting bronchodilators
for 4 hours and oral medicines such as beta-2 agonists, xanthene derivatives for 12
hours, and alcohol or caffeine-contained drink for at least eight hours prior to the test.
Otherwise, participants could intake other foods before the exam. The chest skin was
abraded using gel and then cleaned using alcohol to reduce electrode impedance prior
to the attachment of electrocardiogram (ECG) electrodes. Prior to the examination,
recordings of blood pressure, heart rate, and oxygen saturation were obtained. The
subjects wore a pulse oximeter on the index finger and ECG electrodes on the chest
wall. Before the exam, the breathing tube was inserted into the subject’s mouth with
their lips are sealed around the mouthpiece and the nose clip of the nares was used [23]. The subject was instructed to practice breathing at tidal volume for 1 minute then complete exam in the same way when they were ready. ECG signals and flow signals were recorded continuously for 5 min using three Actiwave devices (CamNtech Ltd, Cambridge, UK). The recorded signals were transferred in European Data Format to LabChart 8 software (ADInstruments, Dunedin, New Zealand), and then exported to text files for analysis.

**Signal Processing and Synchrogram index**

R peaks were detected using a standard R peak detection algorithm from the ECG signal (Figure 2 (a5 and b5)). The time differences between consecutive R peaks were calculated, and then converted into an instantaneous heart rate (IHR) time series using a standard interpolation algorithm (Figure 2 (a4 and b4)) [24]. The phase of the respiratory signal (denoted as $\phi_R$) was extracted using the synchrosqueezing transform (SST) (Figure 2 (a3 and b3) [25]. The phase of IHR (denoted as $\phi_H$) was extracted by the same method (Figure 2 (a2 and b2). After obtaining the phases of the IHR and the respiratory signal, the synchrogram was used to quantify the cardiorespiratory coupling [14, 26]. The output is the synchrogram index, which is a non-unit quantity between 0 and 1. When the cardiorespiratory coupling is strong, the synchrogram index is close to 1; otherwise it is close to 0.
The synchrogram is a signal processing tool used to depict coupling between two oscillatory signals. In the current study, we first obtained the timestamps $t_k$ (Figure 2 (dashed line between a2 and a3, b2 and b3)), where the IHR phase attained 0 modulo $2\pi$. We then measured the respiratory phase at $t_k$ as follows: 

$$\psi(t_k) = \frac{1}{2\pi} [\phi_R(t_k) \ mod \ 2\pi];$$

that is, we evaluate the phase of the respiratory signal at $t_k$ (Figure 2 (circle points at a2 and b2)). Finally, plot $\psi(t_k)$ against $t_k$. When the cardiorespiratory coupling is strong, the phase of the respiratory signal at $t_k$ would be fixed for all $k$, and hence we obtain a horizontal stripe in the plot (Figure 2 (a6)); otherwise, we obtained scattered points in the plot (Figure 2 (b6)). The synchrogram index $\lambda$ [26] is aiming to quantify if the plot is scattered or fixed along a horizontal line. It is defined by

$$\lambda = \frac{1}{M} \left[ \left( \sum_{k=1}^{M} \sin 2\pi \psi(t_k) \right)^2 + \left( \sum_{k=1}^{M} \cos 2\pi \psi(t_k) \right)^2 \right],$$

where $M$ is the number of detected cycles in the IHR.

**Statistical Analysis**

All results are presented as median (range) or mean ± standard deviation. The nonparametric exact two-tailed Mann-Whitney U test was used to determine the statistical significance between two groups of continuous variables, and Fisher’s exact tests were used for categorical variables. Pearson’s correlation was used to examine the association between six-minute walking distance (6MWD), distance saturation product (DSP) and clinical parameter, including synchrogram index. Multivariable
regression analysis was used to determine the independent parameters that predict distance. K-Means was applied to cluster COPD patients based on their synchrogram indices. Silhouette analysis was performed to select optimal cluster numbers. All reported P values were two-sided, with P < 0.05 considered statically significant. Signals were analyzed using Matlab. All data were analyzed using R version 3.5.2 (R foundation for statistical computing).

Results

Demographic characteristics of patient

Among 55 COPD patients, 54 (98.2%) were male, 49 (89.1%) had smoking history, 36 (65.5%) were in allergic status, 33 (60%) were confirmed with emphysema from chest HRCT, and only 1 (1.8%) patient fulfilled the criteria of Asthma-COPD overlap (ACO) [27, 28]. The median synchrogram indices in the COPD group was 0.87 and the distribution was skewed (range: 0.02-0.97). The median BMI was 24.7 (range 16.7-32.1) modified medical research council (mMRC) was 1 (range 0-4), and COPD assessment test (CAT) was 10 (range 2-29). The median ejection fraction was 65.5% (range 52-90), suggesting that there was no heart failure mid-range ejection fraction (HFmrEF) patient in COPD group. However, there were 24 patients (44.3%) presented diastolic dysfunction. The median left atrial size was 34 mm (range 23-46) and E/e’ ratio (the ratio of the transmitral early peak
velocity over early diastolic mitral annulus velocity) was 8.9 (4.5-20.0). In addition, the median eosinophil count was 129 (range 0-615.6), IgE level was 59.7 (2-1652) and 19 (34.5%) patients had a history of acute exacerbation one year prior to enrollment in the study. Most patients used combination therapy of long-acting β2 agonist (LABA) with long-acting muscarinic antagonist (LAMA) (20 (36.4%)) and triple therapy of LABA with LAMA and ICS (26 (47.3%)) (Table 1).

**ECG, flow signal, CRC data, and synchrogram index**

Figures 2a and 2b illustrate CRC analysis based on the synchrogram of IHR and respiratory flow signals. Since there are no definitions of good or poor synchronization, we applied K-means [29]. Two clusters were identified, i.e. synchronized group (n=43) and desynchronized group (n=12) according to the optimal cluster number based on the silhouette analysis. The median synchrogram index values in these two groups were as follows: synchronized group (0.89; 0.64-0.97) and desynchronized group (0.23; 0.02-0.51) (Figure 3b). Overall, subjects in the synchronized group were younger (69 (51-84) vs 77 (52-84), p= 0.02) and had a lower BMI (24.2 (16.7-32) vs 26.2 (20.3-30.8), p =0.03). No significant between-group differences were observed in terms of gender, smoking status, allergic status, therapies, or history of acute exacerbation (Table 1).

**Comparing coupling tests with six-minute walking test**
In terms of 6MWT, patients in the synchronized group presented longer walking distances (468 (328-624) vs. 408 (182-517), unit=m, p =0.009) and a higher distance saturation product (DSP) (421.2 (255.6-536.6), vs 373.2 (149.2-464.6), unit=m%, p=0.02) (Table 2). The correlation of distance and DSP assessed by 6MWT with clinical parameters were listed (Table 3). The synchrogram index correlated significantly with distance (r=0.42, p =0.001) (Figure 3c) and DSP (r=0.41, p= 0.001) (Figure 3d). In the multivariable regression model, age, mMRC and synchrogram index were independent variables that could predict distance. Age, synchrogram index, mMRC, emphysema were independent variables to predict DSP (Table 4).

Distance was explained by the following multivariable regression model with three independent variables: (1) Distance = 671.3+93.3×Synchrogram Index-3.1×Age-37.9×mMRC (r²= 0.56, p <0.0001) (2) DSP= 619.2+89.1×Synchrogram Index-2.8×Age-50.7×mMRC-41.1×Emphysema (r²= 0.63, p <0.0001).

Discussion

This is the first study to cluster COPD patients into synchronized or desynchronized patients in terms of cardiorespiratory coupling. The synchrogram index distribution was wide among COPD patients and narrow among control subjects. Patients in synchronized group presented the similar distribution of synchrogram index to that among control subjects and had higher 6MWD and DSP
compared with desynchronized group. In addition to the factors previously identified, synchrogram index is a novel factor that was and independent variable to predict 6MWD and DSP.

Researchers have previously demonstrated that six-minute walking distance is an important predictor of survival in COPD patients [30, 31] and heart failure patients [32]. The poor walking distance demonstrated by COPD patients can be attributed to age [33], desaturation [34], the severity of emphysema [35], dyspnea scores [36], and inspiratory capacity [37]. Our study has the coordinate results that age and mMRC contribute to 6MWD, and reveal that synchrogram index is a factor in determining 6MWD. The influence of cardiorespiratory coupling on the prognosis of COPD patients should be further confirmed under adequate follow-up duration.

In terms of patients with heart failure, several comorbid conditions, such as skeletal muscle dysfunction, impaired autonomic regulation, and nutritional factors, may coexist and contribute to exercise intolerance [38]. Furthermore, impaired aerobic function due to negative cardiopulmonary muscular interaction contributes to low exercise intolerance in patients with COPD and in those suffering from heart failure [39]. In this study, there is no HFmrEF patient. Moreover, we found that diastolic heart failure was not related to walking distance. This is an indication that walking distance is independent of impaired pulmonary or heart function. Instead, it
appears that nutritional status, peripheral muscle condition [40], oxygen utilization by peripheral muscle, and negative cardiorespiratory-muscle interactions [39] should be taken into account. Since synchrogram index is a quantification of heart lung interaction, its relationship with oxygen utilization by peripheral muscle and cardiopulmonary muscle interactions should be further explored to explain the underlying mechanism why synchrogram index was associated with walking distance.

DSP is a reliable factor to predict mortality among patients with bronchiectasis [41], interstitial lung disease [42], and COPD [43, 44]. In this study, patients in the desynchronized group present a lower DSP, implying an elevated likelihood of poor outcomes but need adequate follow-up duration to confirm. To our knowledge, this is the first study to evaluate factors that associated with DSP in COPD patients. Age, mMRC, synchrogram index and emphysema are independent variables to predict DSP. Emphysema is an independent factor in determining DSP but not 6MWD in this study, which may be related to the correlation of emphysema among desaturation during exercise [45] and its contribution to the desaturation component of DSP.

A strong heart-lung interaction may improve ventilation and perfusion matching, resulting in a better oxygen transport [46]. However, we did not observe any discrepancy between the synchronized and desynchronized groups in terms of saturation. This may be explained by the fact that we excluded patients who were
using oxygen on a daily basis and by the reason that there was similar proportion of emphysema. Note that there may be a link between desaturation and coupling in those patients. In order to evaluate this relationship, it is necessary to explore COPD patients with chronic hypoxemic failure in the next program.

This study faced a number of limitations. First, despite measuring and quantifying the coupling between respiration flow signals and IHR, we found no indications of causality. Second, the strict inclusion criteria prevented us from analyzing patients using oxygen on a daily basis, thus there was small population of desynchronized subgroup in this study. Third, most of the patients in the study were male and all were of East Asian decent; i.e., this sample is not representative of COPD patients overall. Finally, this is a cross-sectional and preliminary data of a prospective-designed study. Due to the insufficient follow-up time, we cannot evaluate mortality outcomes and cardiac vascular events. We will continue monitoring the subjects in this study in order to observe the clinical impact of synchronization in heart-lung interactions.

**Conclusions**

This study first conducted the CRC analysis to describe heart-lung interactions of COPD patients. Asides from age and mMRC, synchrogram index is an independent variable that could predict 6MWD and DSP.
List of abbreviations: ACO: Asthma-COPD overlap; AE: acute exacerbation;
BMI: body mass index; CAT: chronic obstructive pulmonary disease assessment test;
COPD: chronic obstructive pulmonary disease; CRC: cardiorespiratory coupling;
ECG: electrocardiogram; ETCO$_2$ sensor: end tidal CO$_2$ sensor; FEV$_1$: forced expiratory volume in 1st second; FVC: forced vital capacity; GOLD: Global Initiative for Obstructive Lung Disease Criteria; HRV: heart rate variability; HS-CRP: high sensitivity C-reactive protein; ICS: inhaled corticosteroids; IHR: instantaneous heart rate; mMRC: modified medical research council; LABA: long-acting beta agonists;
LAMA: long-acting antimuscarinic agents; OCS: oral corticosteroids; SST:
synchrosqueezing transform

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Chang Gung Memorial Hospital, Linkou, Taiwan (201702150B0). Patients provided signed informed consent prior to screening.

Consent for publication
Not Applicable.
Availability of data and materials

The data sets analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

All authors all declare that they have no competing interests.

Funding

This study was supported by a grant from the Taiwan Ministry of Science and Technology, 107-2314-B-182A-145-MY2.

Authors' contributions

TYL, HTW, PJC, CYL and YLL conceived and designed the analysis. SML MHH, FTC, TYW and HCL contributed to the clinical and laboratory work for the study. YLL, HTW, and YCH designed and performed the statistical analyses. All authors were involved in data analysis, data interpretation, and preparation of the final manuscript. The authors read and approved the final manuscript.

Acknowledgements

We thank all the investigators and members of the Department of Thoracic Medicine for their effort.
References:

1. Scichilone N, Bruno A, Marchese R, et al. Association between reduced bronchodilatory effect of deep inspiration and loss of alveolar attachments. Respiratory research. 2005; 6(1): 55.

2. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. New England Journal of Medicine. 2011; 365(17): 1567-75.

3. Global Initiative For Chronic Obstructive Lung Disease pocket guide to COPD diagnosis, management, and prevention. 2020.

4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine. 2007; 176(6): 532-55.

5. Fabbri LM, Luppi F, Beghè B, et al. Complex chronic comorbidities of COPD. European Respiratory Journal. 2008; 31(1): 204-212.

6. Godtfredsen NS, LAM TH, Hansai TT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. European Respiratory Journal. 2008; 32(4): 844-53.

7. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011; 139(1): 165-73.

8. Elstad M, O’Callaghan EL, Smith AJ, et al. Cardiorespiratory interactions in humans and animals: rhythms for life. American Journal of Physiology-Heart and Circulatory Physiology. 2018; 315(1): 6-17.

9. Baekey DM, Dick TE, Paton JF. Pontomedullary transection attenuates central respiratory modulation of sympathetic discharge, heart rate and the baroreceptor reflex in the in situ rat preparation. Experimental physiology. 2008; 93(7): 803-16.

10. Lopes OU, Palmer J. Proposed respiratory ‘gating’mechanism for cardiac slowing. Nature. 1976; 264(5585): 454.

11. Ben-Tal A, Shamaiov SS, Paton JF. Central regulation of heart rate and the appearance of respiratory sinus arrhythmia: New insights from mathematical modeling. Mathematical biosciences. 2014; 255: 71-82.

12. Elstad M. Respiratory variations in pulmonary and systemic blood flow in healthy humans. Acta physiologica. 2012; 205(3): 341-8.

13. De Burgh Daly, M. Interactions between respiration and circulation. Comprehensive Physiology. 2011; 529-94.

14. Schäfer C, Rosenblum MG,Kurths J et al. Heartbeat synchronized with
ventilation. nature. 1998. 392(6673): 239.

15. Mrowka R, Patzak A, Rosenblum M, et al. Quantitative analysis of
cardiorespiratory synchronization in infants. International Journal of
Bifurcation and Chaos. 2000. 10(11): 2479-88.

16. Niizeki K, Saitoh T. Association between phase coupling of respiratory sinus
arrhythmia and slow wave brain activity during sleep. Frontiers in physiology.
2018; 9: 1338.

17. Cheyne WS, Williams AM, Harper MI, et al. Heart-lung interaction in a model
of COPD: importance of lung volume and direct ventricular interaction.
American Journal of Physiology-Heart and Circulatory Physiology. 2016.
311(6): 1367-74.

18. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based
on severity of emphysema in chronic obstructive pulmonary disease. Thorax.
2007; 62(11): 932-7.

19. Rodriguez-Roisin R. Toward a Consensus Definition for COPD
Exacerbations. CHEST. 2000; 117: 398-401.

20. Przybyłowski T, Tomalak W, Siergiejko Z, et al. Polish Respiratory Society
guidelines for the methodology and interpretation of the 6 minute walk test
(6MWT). Advances in Respiratory Medicine. 2015; 83(4): 283-97.

21. Crapo RO, Hankinson JL, Irvin C, et al. Standardization of spirometry: 1994
update. American Journal of Respiratory and Critical Care Medicine. 1995;
152(3): 1107-36.

22. ATS committee on proficiency standards for clinical pulmonary function
laboratories. Am J Respir Crit Care Med. 2002; 166(1): 111-7.

23. Miller MR, Hankinson JATS, Brusasco V, et al. Standardisation of spirometry.
European respiratory journal. 2005; 26(2): 319-38.

24. Camm AJ, Malik M, Bigger JT, et al. Heart rate variability: standards of
measurement, physiological interpretation and clinical use. Task Force of the
European Society of Cardiology and the North American Society of Pacing
and Electrophysiology. 1996.

25. Daubechies I, Lu J,Wu HT, et al. Synchrosqueezed wavelet transforms: An
empirical mode decomposition-like tool. Applied and computational harmonic
analysis. 2011;30(2): 243-61.

26. Nguyen CD, Wilson SJ, Crozier S, et al. Automated quantification of the
synchrogram by recurrence plot analysis. IEEE Transactions on Biomedical
Engineering. 2012; 59(4): 946-55.

27. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma– COPD overlap
syndrome? Towards a consensus definition from a round table discussion.
European Respiratory Journal. 2016; 48(3): 664-73.

28. Maselli DJ, Hardin M, Christenson SA, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest. 2019; 155(1): 168-77.

29. Hartigan J, Wong M. AK-Means Clustering Algorithm. Journal of the Royal Statistical Society Series C. 1979; 28(1): 100-8.

30. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. American journal of respiratory and critical care medicine. 2013; 187(4): 382-6.

31. Pinto-Plata V, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. European Respiratory Journal. 2004; 23(1): 28-33.

32. Rubim, V.S.M., et al., Prognostic value of the six-minute walk test in heart failure. Arquivos brasileiros de cardiologia, 2006. 86(2): p. 120-125.

33. Peruzza S, Sergi, G, Vianello, A, et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. Respiratory medicine. 2003; 97(6): 612-7.

34. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respiratory medicine. 2010; 104(6): 849-57.

35. Díaz AA, Pinto-Plata V, Hernández C, et al. Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. Respiratory medicine. 2015; 109(7): 882-9.

36. Guo Y, Zhang X, Chen J, et al. Value of CAT and mMRC in clinical evaluation of chronic obstructive pulmonary disease. Chongqing Medicine, 2014; (11): 1304-7.

37. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2001; 163(6):1395-9.

38. Del Buono MG, Arena R, Borlaug BA, et al. Exercise intolerance in patients with heart failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019; 73(17): 2209-25.

39. Rocha A, Arbex FF, Sperandio PA, et al. Exercise intolerance in comorbid COPD and heart failure: the role of impaired aerobic function. European Respiratory Journal. 2019; 53(4): 1802386.

40. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve: Official
Journal of the American Association of Electrodiagnostic Medicine. 2010; 41(4): 500-10.

Hsieh MH, Fang YF, Chung FT, et al. Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. Journal of thoracic disease. 2017; 9(9): 3168.

Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respiratory medicine. 2006; 100(10): 1734-41.

Andrianopoulos V, Wouters EF, Pinto-Plata VM, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: results from the ECLIPSE study. Respiratory medicine. 2015; 109(9): 1138-46.

Gurbani N, Figueira Gonçalves JM, García Bello MA, et al. Prognostic ability of the distance-saturation product in the 6-minute walk test in patients with chronic obstructive pulmonary disease. The Clinical Respiratory Journal. 2020; 14(4): 364-9.

Andrianopoulos V, Celli BR, Franssen FM, et al. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory medicine. 2016; 119: 87-95.

Yasuma F, Hayano J. Respiratory sinus arrhythmia: why does the heartbeat synchronize with respiratory rhythm? Chest. 2004; 125(2): 683-90.
| Variable                  | Total       | Synchronized | Desynchronized | p-value |
|---------------------------|-------------|--------------|----------------|---------|
| Age                       | 69 (51-84)  | 69 (51-84)   | 77 (52-84)     | 0.02    |
| Gender, male              | 54 (98.2)   | 42 (97.7)    | 12 (100)       | 1       |
| Smoker                    | 49 (89.1)   | 38 (88.4)    | 11 (91.7)      | 1       |
| Current                   | 27 (49.1)   | 20 (46.5)    | 7 (58.3)       | 1       |
| Ex-smoker                 | 22 (40)     | 17 (39.5)    | 5 (41.7)       | 1       |
| BMI                       | 24.7 (16.7-32.1) | 24.2 (16.7-32.0) | 26.2 (20.3-30.8) | 0.03    |
| Eosinophil Count          | 129 (0-615.6) | 134.5 (0-615.6) | 115.0 (0-329.8) | 0.74    |
| Allergy                   | 36 (65.5)   | 28 (65.1)    | 8 (66.7)       | 1       |
| a-IgE                     | 59.7 (2-1652) | 65.2 (3.59-1652) | 47.0 (2-691)   | 0.59    |
| HS-CRP                    | 1.7 (0.2-189.7) | 1.64 (0.2-37.9) | 1.75 (0.2-189.7) | 0.65    |
| CAT                       | 10 (2-29)   | 10 (2-29)    | 6 (3-29)       | 0.99    |
| mMRC                      | 1 (0-4)     | 1 (0-3)      | 1 (0-4)        | 0.73    |
| Emphysema                 | 33 (60)     | 27 (62.7)    | 6 (50)         | 1       |
| AE history                | 19 (34.5)   | 16 (37.2)    | 3 (25)         | 0.49    |
| Underlying                |             |              |                |         |
| ACO                       | 1 (1.8)     | 0 (0)        | 1 (8.3)        | 0.21    |
| Hypertension              | 17 (30.9)   | 11 (25.6)    | 6 (46.2)       | 0.16    |
| DM                        | 8 (14.5)    | 5 (11.6)     | 3 (23.1)       | 0.35    |
| CAD                       | 3 (5.5)     | 3 (7.0)      | 0 (0)          | 1       |
| Liver Disease             | 6 (10.9)    | 6 (14.0)     | 0 (0)          | 0.32    |
| Kidney Disease            | 1 (1.8)     | 0 (0)        | 1 (7.7)        | 0.21    |
| Cardiac echo              |             |              |                |         |
| Diastolic dysfunction     | 24 (43.6)   | 20 (46.5)    | 4 (33.3)       | 0.51    |
| E/e' ratio                | 8.9 (4.5-20.0) | 8.8 (4.5-13.0) | 11.4 (5.2-20.0) | 0.06    |
| EF (%)                    | 65.5 (52-90) | 66.5 (52-90) | 64.5 (52-78)   | 0.33    |
| LA (mm)                   | 34 (23-46)  | 34 (23-46)   | 33.5 (28-41)   | 0.99    |
| Drugs                     |             |              |                |         |
| LABA                      | 4 (7.3)     | 3 (7.0)      | 1 (8.3)        | 1       |
| LAMA                      | 1 (1.8)     | 1 (2.3)      | 0 (0)          | 1       |
| LABA+LAMA                 | 20 (36.4)   | 15 (34.9)    | 5 (41.7)       | 0.74    |
| LABA+ICS                  | 3 (5.5)     | 2 (4.7)      | 1 (8.3)        | 0.54    |
| Triple                    | 26 (47.3)   | 22 (51.2)    | 4 (33.3)       | 0.35    |
| OCS                       | 5 (9.1)     | 4 (9.3)      | 1 (8.3)        | 1       |
| Anti-psychotic agents     | 2 (3.6)     | 0 (0)        | 2 (4.8)        | 1       |
Significantly different from patients with synchronized and desynchronized (P < 0.05). Abbreviation: BMI (Body mass index), HS-CRP (High sensitivity C reactive protein), CAT (Chronic obstructive pulmonary disease assessment test), mMRC (modified medical research council), E/e' ratio (the ratio of the transmitral early peak velocity over early diastolic mitral annulus velocity), EF (Ejection fraction), LA (left atrial) LABA (Long acting beta agonists), LAMA (Long acting antimuscarinic agents), ICS (inhaled corticosteroids), Triple (LABA+LAMA+ICS), OCS (oral corticosteroids), AE (acute exacerbation)
### Table 2 Results of 6MWT in COPD patients, synchronized and desynchronized group

| Variable                  | COPD (n=55) | Synchronized (n=43) | Desynchronized (n=12) | p-value |
|---------------------------|-------------|---------------------|-----------------------|---------|
| Median (range)            |             |                     |                       |         |
| Pre-FVC (L)               | 2.6 (1.2-4.4) | 2.7 (1.2-4.4)      | 2.45 (1.3-3.3)        | 0.28    |
| Pre-FVC (%)               | 78.7 (38-129)| 82.5 (39-129)      | 77 (38-96)            | 0.89    |
| Pre-FEV1 (L)              | 1.5 (0.5-2.7)| 1.39 (0.6-2.7)     | 1.43 (0.5-2.0)        | 0.49    |
| Pre-FEV1 (%)              | 56.7 (18-102)| 55.5 (18-102)      | 62.5 (18-76)          | 0.79    |
| Pre-FEV1/FVC              | 0.56 (0.31-0.72) | 0.57 (0.31-0.72) | 0.56 (0.35-0.7)      | 0.64    |
| Post-FVC (L)              | 2.7 (1.1-4.4) | 2.7 (1.1-4.4)      | 2.7 (1.4-3.3)         | 0.29    |
| Post-FVC (%)              | 81 (42-130)  | 81.5 (42-130)      | 87 (43-96)            | 0.78    |
| Post-FEV1 (L)             | 1.47 (0.53-2.82) | 1.44 (0.67-2.82) | 1.49 (0.53-2.09)     | 0.53    |
| Post-FEV1 (%)             | 60 (21-105)  | 57 (22-105)        | 60 (21-79)            | 0.60    |
| Post-FEV1/FVC             | 0.59 (0.35-0.73) | 0.59 (0.35-0.73) | 0.56 (0.37-0.70)     | 0.62    |
| Pre-HR                    | 83 (57-109)  | 83.5 (57-109)      | 80.5 (60-98)          | 0.66    |
| Post-HR                   | 107 (69-149) | 108 (69-149)       | 105 (70-122)          | 0.48    |
| Pre-Borg                  | 0 (0-3)      | 0 (0-3)            | 1 (0-3)               | 0.06    |
| Post-Borg                 | 4 (1-7)      | 4 (2-7)            | 4 (1-7)               | 0.77    |
| pre-spO2                  | 95 (88-99)   | 95.5 (88-99)       | 95 (90-98)            | 0.31    |
| post-spO2                 | 90.5 (75-96) | 90.5 (75-96)       | 90 (80-95)            | 0.61    |
| pre-IC                    | 1.78 (0.92-2.77) | 1.78 (1.07-2.77) | 1.73 (0.92-2.04)     | 0.20    |
| post-IC                   | 1.73 (0.94-2.83) | 1.73 (0.97-2.83) | 1.7 (0.94-2.43)      | 0.45    |
| ΔIC                       | 0 (-1.1-0.55) | -0.02 (-0.49-0.55) | 0.11 (-1.1-0.28)     | 0.37    |
| ΔspO2                     | -4.5 (-22-0) | -4.5 (-22-0)       | -4.0 (-18-0)          | 0.97    |
| Distance                  | 456 (182-624) | 468 (328-624)     | 408 (182-517)         | 0.03    |
| DSP                       | 411.1 (149.2-536.6) | 421.2 (255.6-536.6) | 373.2 (149.2-464.6) | 0.04    |

Significantly different from patients with Synchronized and Desynchronized (P < 0.05). Abbreviation: 6MWT (six minutes walking test), FVC (Forced vital capacity), FEV1 (Forced expiratory volume in 1st second), HR (Heart rate), ΔIC (change of inspiratory capacity), ΔspO2 (change of oxyhemoglobin saturation by pulse oximetry), DSP (Distance saturation product)

### Table 3 Main correlations with distance and DSP as Assessed by 6MWT

| Variable     | Distance r Value | Distance p Value | DSP r Value | DSP p Value |
|--------------|-----------------|------------------|-------------|-------------|
| Age          | -0.53           | <0.001           | -0.53       | <0.001      |
| Synchrogram Index | 0.42             | 0.001            | 0.41        | 0.001       |
| BMI          | -0.07           | 0.62             | -0.05       | 0.69        |
| Gender       | 0.13            | 0.34             | 0.17        | 0.21        |
| CAT          | -0.44           | <0.001           | -0.44       | <0.001      |
| mMRC         | -0.53           | <0.001           | -0.61       | <0.001      |
| Smoking      | 0.02            | 0.86             | 0.03        | 0.83        |
Table 4-1 Multivariable regression model for distance as assessed by 6MWT

| variable            | Beta  | *SE  | t value | p-value |
|---------------------|-------|------|---------|---------|
| Age                 | -3.1  | 1.2  | -2.6    | 0.01    |
| Synchrogram Index   | 93.3  | 42.2 | 2.2     | 0.03    |
| mMRC                | -37.9 | 12.9 | -2.9    | 0.005   |

$r^2= 0.56$, adjusted $r^2 = 0.51$, Residual stand error = 60.9, $p<0.0001$, Abbreviation: *SE: stand error of beta.

Distance = 671.3+93.3XSynchrogram Index-3.1XAge-37.9XmMRC

Table 4-2 Multivariable regression model for DSP as assessed by 6MWT

| variable            | Beta  | *SE  | t value | p   |
|---------------------|-------|------|---------|-----|
| Age                 | -2.8  | 1.1  | -2.4    | 0.02|
| Synchrogram Index   | 89.1  | 39.0 | 2.3     | 0.03|
| CAT score           | -0.9  | 1.6  | -0.6    | 0.57|
| mMRC                | -40.7 | 14.3 | -2.8    | 0.007|
| Emphysema           | -41.1 | 19.6 | -2.1    | 0.04|

$r^2= 0.63$, adjusted $r^2 = 0.58$, Residual stand error = 56.3, $p<0.0001$, Abbreviation: DSP (Distance saturation product), SE: Stand error of beta. DSP = 619.2+89.1XSynchrogram Index-2.8XAge-50.7XmMRC-41.1*Emphysema
Legends

Figure 1 Flow chart.

Figure 2 (a1) respiratory flow signal (a2) phase of the flow signal extracted by the SST, (a3) phase of the IHR extracted by the synerosqueezing transform (SST), (a4) instantaneous heart rate (IHR), (a5) Electrocardiogram, (a6) synchrogram during 110 (sec) to 125 (sec) (a7) synchrogram and the resulting synchrogram index (0.89) in a synchronized patient.

(b1) respiratory flow signal (b2) phase of the flow signal extracted by the SST, (b3) phase of the IHR extracted by the SST, (b4) IHR, (b5) Electrocardiogram, (b6) synchrogram during 110 (sec) to 125 (sec) (b7) synchrogram and its synchrogram index (0.35) in a desynchronized patient.

Figure 3 (a) Distribution of synchrogram index in synchronized group and desynchronized group. (b) Scatterplot of synchrogram index against distance (m) from six-minute walking test of all patients (c) Scatterplot of synchrogram index against distance saturation product (m%) from six-minute walking test of all patient